<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82482">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02144948</url>
  </required_header>
  <id_info>
    <org_study_id>PUNiDIA-2014</org_study_id>
    <nct_id>NCT02144948</nct_id>
  </id_info>
  <brief_title>Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II</brief_title>
  <acronym>PUNiDIA</acronym>
  <official_title>Pilot Study to Investigate the Effect of E-coli-nissle as Probiotic Adjuvant to Antidiabetic Standard Care in Patients With Diabetes Mellitus Type II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARDEYPHARM GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to
      antidiabetic standard care in patients with diabetes mellitus type II
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Decrease in HbA1c levels</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in insulin resistance/secretion</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lipid parameters</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in parameters of oxidative stress</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in gastrointestinal condition</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Mellitus Type II</condition>
  <arm_group>
    <arm_group_label>E.-coli-Nissle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>e.-coli-nissle</intervention_name>
    <description>1 ml qd for 24 weeks</description>
    <arm_group_label>E.-coli-Nissle</arm_group_label>
    <other_name>Mutaflor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes mellitus type 2;

          -  HbA1c &gt;7 % (stable für 6 months, max. variation of 0,5%)

          -  stable oral antidiabetic therapy for 6 months with Metformin, Vildagliptin, Gliniden
             or without oral Antidiabetics

          -  age of 45 to &lt;80 years (men and women)

        Exclusion Criteria:

          -  Myocardial infarction or stroke within the last 5 years

          -  Therapy with acarbose

          -  Acute peripheral arterial disease within the last 12 months

          -  Instable metabolic situation

          -  Uncontrolled hypertension

          -  Body-Mass-Index ≥ 35 kg/m²

          -  Smokers

          -  Daily consumption of probiotic food

          -  Malignant disease within the last 5 years

          -  Status post transplantation

          -  Immunosuppressive therapy within the last 3 months

          -  Therapy with antibiotics

          -  Macroalbuminuria

          -  Severe liver disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antje Bergmann, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carus Hausarztpraxis on behalf of GWT-TUD GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan R. Bornstein, Prof. Dr. med</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Dresden on behalf of GWT-TUD GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Schulze</last_name>
    <email>martina.schulze@gwtonline.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carus-Hausarztpraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antje Bergmann, Prof. Dr. med.</last_name>
      <phone>0049351314439</phone>
      <phone_ext>0</phone_ext>
      <email>antje.bergmann@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Uta-Katharina Schmidt-Göhrich</last_name>
      <phone>0049351314439</phone>
      <phone_ext>0</phone_ext>
      <email>katharina.schmidt@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Antje Bergmann, Prof. Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
